论文部分内容阅读
目的分析西格列汀治疗肥胖2型糖尿病的临床治疗效果。方法回顾性分析本院83例肥胖2型糖尿病患者的临床资料。结果两组患者治疗前,糖化血红蛋白(HbA1C)、餐后2h血糖(2hPG)、空腹血糖(FPG)指标对比差异无统计学意义(P>0.05);两组患者治疗后,糖化血红蛋白(HbA1C)、餐后2h血糖(2hPG)、空腹血糖(FPG)指标下降幅度均优于对照组各指标下降幅度,差异有统计学意义(P<0.05)。结论采用西格列汀治疗肥胖2型糖尿病,可有效降低患者糖化血红蛋白、餐后血糖以及患者空腹血糖,毒副作用小,其治疗效果显著,值得在临床推广使用。
Objective To analyze the clinical effect of sitagliptin in the treatment of obese type 2 diabetes mellitus. Methods The clinical data of 83 obese type 2 diabetic patients in our hospital were retrospectively analyzed. Results Before treatment, there was no significant difference in HbA1C, 2hPG and FPG between the two groups (P> 0.05). After treatment, the levels of HbA1C, , Postprandial 2h blood glucose (2hPG), fasting blood glucose (FPG) decreased more significantly than the control group, the difference was statistically significant (P <0.05). Conclusion Sitagliptin treatment of type 2 diabetes mellitus can reduce glycosylated hemoglobin, postprandial blood glucose and fasting blood glucose in patients with small toxic and side effects, its therapeutic effect is significant and worthy of clinical promotion and use.